Fate Therapeutics Inc
FATENasdaqCIK 1434316HealthcareFiscal year ends Dec 31
Reports and events: 223 filings
Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.
What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2026-09-2808:10 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-403429 |
| 2026-08-1308:34 ET | 10-Q | Quarterly reportPeriod 2026-06-30 | 0001193125-26-347988 |
| 2026-08-1308:31 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-347984 |
| 2026-06-1516:02 ET | 8-K | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001193125-26-271055 |
| 2026-06-0416:37 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-257558 |
| 2026-05-1308:34 ET | 10-Q | Quarterly reportPeriod 2026-03-31 | 0001193125-26-220696 |
| 2026-05-1308:32 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-220691 |
| 2026-04-2416:03 ET | DEF 14A | Proxy statementPeriod 2026-06-12 | 0001193125-26-177094 |
| 2026-04-2221:47 ET | SCHEDULE 13D/A | Ownership report, active investor, amended | 0001104659-26-047066 |
| 2026-02-2609:07 ET | 10-K | Annual reportPeriod 2025-12-31 | 0001193125-26-073699 |
| 2026-02-2609:04 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-073689 |
| 2025-11-1308:35 ET | 10-Q | Quarterly reportPeriod 2025-09-30 | 0001193125-25-279096 |
| 2025-11-1308:32 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-25-279091 |
| 2025-10-2707:00 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-25-250674 |
| 2025-10-1416:02 ET | 8-K | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-25-238989 |
| 2025-08-1216:09 ET | 10-Q | Quarterly reportPeriod 2025-06-30 | 0000950170-25-107309 |
| 2025-08-1216:07 ET | 8-K | 2.02 Results of operations; 2.05 Exit or disposal costs; 9.01 Financial statements and exhibits | 0001193125-25-178947 |
| 2025-07-0316:01 ET | SCHEDULE 13D/A | Ownership report, active investor, amended | 0001104659-25-065772 |
| 2025-06-1716:01 ET | 8-K/A | 5.07 Shareholder vote results | 0001193125-25-142037 |
| 2025-05-3017:15 ET | 8-K | 5.02 Departure or appointment of officers or directors; 5.03 Amendment to articles or bylaws; 5.07 Shareholder vote results; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-25-132301 |
| 2025-05-1316:03 ET | 10-Q | Quarterly reportPeriod 2025-03-31 | 0000950170-25-070285 |
| 2025-05-1316:02 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-070280 |
| 2025-04-1716:05 ET | DEF 14A | Proxy statementPeriod 2025-05-29 | 0001193125-25-084310 |
| 2025-03-0516:03 ET | 10-K | Annual reportPeriod 2024-12-31 | 0000950170-25-033510 |
| 2025-03-0516:02 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-033507 |
| 2025-01-0616:01 ET | 8-K | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001193125-25-002153 |
| 2024-12-2621:00 ET | SCHEDULE 13D/A | Ownership report, active investor, amended | 0001104659-24-131793 |
| 2024-11-2914:33 ET | 8-K | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-24-268003 |
| 2024-11-1216:03 ET | 10-Q | Quarterly reportPeriod 2024-09-30 | 0000950170-24-125317 |
| 2024-11-1216:01 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-125307 |
| 2024-08-3016:21 ET | 8-K | 1.01 Entry into a material agreement; 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001193125-24-211130 |
| 2024-08-1316:08 ET | 10-Q | Quarterly reportPeriod 2024-06-30 | 0000950170-24-096187 |
| 2024-08-1316:06 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-096177 |
| 2024-07-3116:03 ET | 8-K | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-24-189911 |
| 2024-06-1016:31 ET | 8-K | 5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits | 0001193125-24-158374 |
| 2024-06-0717:26 ET | 8-K | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001193125-24-157554 |
| 2024-05-3117:24 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001193125-24-151963 |
| 2024-05-0916:05 ET | 10-Q | Quarterly reportPeriod 2024-03-31 | 0000950170-24-056869 |
| 2024-05-0916:02 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-056852 |
| 2024-05-0909:01 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-24-134840 |
| 2024-04-2616:06 ET | DEF 14A | Proxy statementPeriod 2024-06-07 | 0001193125-24-117981 |
| 2024-03-2517:15 ET | SC 13D/A | Ownership report, active investor, amended | 0001104659-24-038492 |
| 2024-03-2117:32 ET | 8-K | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-24-072871 |
| 2024-02-2616:10 ET | 10-K | Annual reportPeriod 2023-12-31 | 0000950170-24-020158 |
| 2024-02-2616:03 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-020123 |
| 2023-12-2816:53 ET | SC 13D/A | Ownership report, active investor, amended | 0001104659-23-130098 |
| 2023-11-0817:10 ET | 8-K | 1.01 Entry into a material agreement; 1.02 Termination of a material agreement; 9.01 Financial statements and exhibits | 0001193125-23-273633 |
| 2023-11-0816:05 ET | 10-Q | Quarterly reportPeriod 2023-09-30 | 0000950170-23-061080 |
| 2023-11-0816:03 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-23-061077 |
| 2023-09-0117:29 ET | 8-K | 8.01 Other events | 0001193125-23-227749 |
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 24, 2026, 15:08 ET. Listed shows no prices and gives no investment advice.